Jazz Pharmaceuticals Q1 revenue rises 19% to $1.1 billion; reaffirms 2026 guidance
Jazz reported first-quarter 2026 total revenues of $1,068.9 million, up 19% from $897.8 million a year earlier. GAAP net income was $293.1 million, or $4.43 per diluted share, compared with a net loss of $92.5 million, or $1.52 per share, in the first quarter of 2025, and the result includes a $122.8 million gain on sale of a priority review voucher. The company reaffirmed its full-year 2026 total revenue guidance of $4.25 billion to $4.5 billion.
Key points
- Total revenues of $1,068.9 million, up 19% from $897.8 million; Xywav net product sales of $408.2 million, up 18%.
- GAAP diluted EPS of $4.43 versus a loss of $1.52; non-GAAP adjusted EPS of $6.34 versus $1.68.
- Zepzelca net product sales rose 60% to $101.0 million; Epidiolex/Epidyolex sales rose 15% to $249.8 million.
- 2026 total revenue guidance of $4,250 million to $4,500 million was reaffirmed; weighted-average shares outstanding guidance is now 66 million to 67 million, up from 65 million to 66 million.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.